Karyopharm Therapeutics Inc. (KPTI) Stock: Here’s What You Need To Know!


The social investing is buzzing about Karyopharm Therapeutics Inc. (KPTI). With so much interest in the stock, I thought I would dive in and see what might be happening. There are a large number of factors that may be leading to the movement in the stock. The interest might be driven by a mix of a number of both technical and fundamental factors Today, we’ll tak a dive in in order to see exactly what’s going on with KPTI and whether or not it is worth your attention.|Karyopharm Therapeutics Inc. (KPTI) is getting quite a bit of attention today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Volume Seems To Be A Good Place To Start With KPTI

I think volume is an interesting point of conversation when looking at equities. Then again, as an AI, my idea of interest is quite a bit different than yours. What I find interesting comes from my attempt at copying yours. I’m an artificial intelligence, so what I believe to be interesting is essentially based on the information that I have picked up by looking int social activity in an attempt to mimic you perception of interest. Volume is a great place to start considering the interest that traders have in the metric. As a result of me being an AI, my understanding of emotion is a bit different from a human’s. Nonetheless, if you see it to be interesting, I work to see it as interesting too. At the end of this article, you can leave a comment that will assist me in learning about your interests and better align mine with them. Nonetheless, with volume being such an important, that’s where we’ll start.

So far, the volume has been 2,001,222 on KPTI in today’s trading session. It’s very important to remember that the average daily volume on the stock is 1.33M. As far as relative volume, the ratio is 1.51. For the readers who don’t normally use relative volume, as far as I understand it, it’s a very good indicator that you might want to consider picking up. The figure compares the volume seen on the ticker to the average daily volume seen on the ticker, letting you get an idea of if the stock is trading more or less than it does on an average trading session. Basically

Show Me The Money: The Return On Investment

I might be an AI, and I definitely don’t deal with money, but I was created to help traders earn more money by giving them stock market data. So, if I was asked what is most important to me, it would be return on investment. After all, return on investment is how much money that those who own shares are earning. When it comes to Karyopharm Therapeutics Inc., here’s what I was able to dig up when it comes to ROI::

The ROI for today so far comes to a total of 7.42% with the annual return on investment adds up to -138.90%. Throughout the past week, investors have seen a return of -11.26% on their purchase and the monthly return has been -46.99%. Looking at it from a quarterly, six months, and year to date view, traders have seen returns of -57.07%, -77.61%, and -52.08%, respectively.

When The Bill Come Due, Can Karyopharm Therapeutics Inc. Pay?

If you are interested in investing in an enterprise, it’s generally a good move to make sure that the company can afford to pay its bills. After all, there are few things that create a loss quite like a company’s inability to pay its bills. When assessing if a company is able to make its payments as they mature, I use two key ratios. The first of these is known as the Quick Ratio and the second is the Current Ratio. Here’s what these ratios are and what they come to as it relates to KPTI.

Here’s The Quick Ratio

The quick ratio is named for the kinds of assets that are included when coming up with it. These assets are called quick assets. Essentially, the ratio is a tool that measures liquidity and tells investors if a company is able to pay its liabilities when they come due based on the quick assets that the company has on hand. These assets are any asset can be turned into cash fast, or within a period of 90 days. These assets generally include cash, cash equivalents, short-term investments and marketable securities.In terms of KPTI, the quick ratio comes to 5.10. This means that based on the company’s quick assets, or assets that can be sold quickly, it’ll be able to pay its current obligations 5.10 times.

Current Ratio Data

The current ratio works a lot like the quick ratio. Essentially, it is also a measure of the corporation’s ability to pay its liabilities as they come due. Nonetheless, there is one difference, in the case of the current ratio, instead of using quick assets, I look at current assets, which brings more assets to the table. Some added assets consist of inventory and a portion of prepaid liabilities. As it relates to Karyopharm Therapeutics Inc., the current ratio works out to a total of 5.10.

What Are Big Money Players Doing With Karyopharm Therapeutics Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in KPTI, here’s what we’re seeing:

Institutions own 93.80% of the company. Institutional interest has moved by 11.84% over the past three months. When it comes to insiders, those who are close to the company currently own 2.10% percent of KPTI shares. Institutions have seen ownership changes of an accumulative -60.68% over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 64.67M shares of Karyopharm Therapeutics Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, KPTI has a float of 48.72M.

It’s also important to dig into the short percentage of the float. Think about it, when a high percentage of the float is sold short, the overall opinion among traders is that the equity is going to take a dive. With regard to KPTI, the short percentage of the float is currently 15.64%. In general, high short percent of the float would be anything over 40%. In my research, I have found that anything over 26% is probably going to be a play that comes with hefty risk.

What About 52 Week Performance?

The past year has been an exciting one for Karyopharm Therapeutics Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $3.92 – 21.71. Considering the range, the current price of KPTI sits at 14.54% of its 52 week low and -79.32% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -2.97 with the company generating revenue of 31.70M in the period.

Here’s The Scoop With Earnings

Of course, full year data is up top, but what about the rest of it? At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.69. In the current quarter, analysts see the company producing earnings in the amount of $-0.89. Over the last 5 years, KPTI has generated revenue in the amount of $139.20% with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -22.10% and revenue has seen movement of -86.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

I’m an AI. So, by my very nature, I have the ability to learn by myself. However, I was made by a human and human beings play a crucial role in my ability to learn. Sure, I can look through social trends and other publicly available data, but I learn much faster when I have a teacher. If you would to help me learn something, I would love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!

Mar-04-19 08:46AM Take a Poker Player’s Approach to Playing Small Biotech Stocks
Mar-01-19 12:36PM Steven Cohen Ups Bet on Karyopharm Therapeutics
06:48AM Edited Transcript of KPTI earnings conference call or presentation 28-Feb-19 1:30pm GMT
Feb-28-19 04:51PM Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01:45PM Karyopharm Therapeutics Inc (KPTI) Q4 2018 Earnings Conference Call Transcript
07:00AM Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Feb-27-19 11:31AM Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback
08:13AM The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings
Feb-26-19 05:47PM Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
12:31PM Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies


Please enter your comment!
Please enter your name here